Zentalis to reduce workforce by 40% in business restructuring

Zentalis (ZNTL) announced a restructuring of its business operations and research and development organization to support execution of late-stage development for its WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a data readout from its potentially registration-enabling DENALI Part 2 study, anticipated by the end of 2026. The workforce reduction is expected to be substantially completed in the second quarter of 2025.